Axitinib eutectic salt

The invention provides an axitinib succinic acid eutectic salt, and relates to the technical field of crystal form drug molecules. The eutectic salt is radiated by Cu-K alpha, and an X-ray diffraction spectrum represented by 2 theta has characteristic peaks at 7.72 +/-0.2 degrees, 8.00 +/-0.2 degrees, 16.09 +/-0.2 degrees, 20.05 +/-0.2 degrees, 21.09 +/-0.2 degrees and 26.05 +/-0.2 degrees; crystal measurement parameters are as follows: a monoclinic system and a space group of P21/c; the cell parameters are as follows: alpha = 90 degrees, beta = 92.0250 (10) degrees and gamma = 90 degrees. The invention also provides a related preparation method and application. The axitinib succinic acid eutectic salt disclosed by the invention is good in stability and relatively high in solubility and permeability. 本发明提供了一种阿昔替尼琥珀酸共晶盐，涉及晶型药物分子技术领域。该共晶盐使用Cu-Kα辐射，以2θ表示的X射线衍射谱图在7.72±0.2°，8.00±0.2°，16.09±0.2°，20.05±0.2°，21.09±0.2°，26.05±0.2°有特征峰；晶体学测量参数是：单斜晶系，空间群为P21/c；晶胞参数为：α＝90°，β＝92.0250(10)°，γ＝90°，晶胞体积并提供了相关制备方法和应用。本发明的阿昔替尼琥